Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-05
DOI
10.1186/s13045-019-0815-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
- (2019) Aytug Kizilors et al. Lancet Haematology
- Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
- (2019) Gabriel Etienne et al. Cancer Medicine
- Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease
- (2018) Susan Branford et al. BLOOD
- Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management
- (2018) Stacy S. Hung et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
- (2018) Yucel Erbilgin et al. LEUKEMIA & LYMPHOMA
- Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
- (2018) Simona Soverini et al. Molecular Cancer
- Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia
- (2018) Massimo Breccia et al. Current Oncology Reports
- Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) A Hochhaus et al. ANNALS OF ONCOLOGY
- Outcomes of 219 chronic myeloid leukaemia patients with additional chromosomal abnormalities and/or tyrosine kinase domain mutations
- (2018) Mingming Xue et al. International Journal of Laboratory Hematology
- Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use
- (2018) Ulrike Bacher et al. Blood Cancer Journal
- Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
- (2017) A Hochhaus et al. LEUKEMIA
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of CML-blast crisis
- (2016) Rüdiger Hehlmann et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
- (2016) Simona Soverini et al. BMC CANCER
- Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia
- (2016) C. Baer et al. HAEMATOLOGICA
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics
- (2016) Maksym Misyura et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
- (2016) Z Chen et al. LEUKEMIA
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- The concept of treatment-free remission in chronic myeloid leukemia
- (2016) S Saußele et al. LEUKEMIA
- Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
- (2016) Simona Soverini et al. Oncotarget
- Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia
- (2016) C. Baer et al. HAEMATOLOGICA
- Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing
- (2015) Philippe Szankasi et al. ANNALS OF HEMATOLOGY
- Management of chronic myeloid leukemia in blast crisis
- (2015) S. Saußele et al. ANNALS OF HEMATOLOGY
- Validation of a Next-Generation–Sequencing Cancer Panel for Use in the Clinical Laboratory
- (2015) Birgitte B. Simen et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation
- (2015) Daniel N. Egan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
- (2015) M. W. Deininger et al. BLOOD
- Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
- (2015) Simona Soverini et al. Clinical Lymphoma Myeloma & Leukemia
- Confirming Variants in Next-Generation Sequencing Panel Testing by Sanger Sequencing
- (2015) Linnea M. Baudhuin et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting
- (2014) L.-A. Sutton et al. HAEMATOLOGICA
- Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase
- (2014) Katerina Machova Polakova et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
- (2013) S. Soverini et al. BLOOD
- Next-generation sequencing - feasibility and practicality in haematology
- (2013) Alexander Kohlmann et al. BRITISH JOURNAL OF HAEMATOLOGY
- The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis
- (2013) F. E. Nicolini et al. HAEMATOLOGICA
- Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
- (2013) Simona Soverini et al. LEUKEMIA RESEARCH
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
- (2012) J. S. Khorashad et al. BLOOD
- BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation
- (2011) Mary Alikian et al. AMERICAN JOURNAL OF HEMATOLOGY
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile
- (2011) W. T. Parker et al. BLOOD
- Sensitive Detection ofBCR-ABL1Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy
- (2011) Wendy T. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories
- (2011) A Kohlmann et al. LEUKEMIA
- Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
- (2010) E. Jabbour et al. BLOOD
- BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
- (2010) D. W. Sherbenou et al. BLOOD
- Mutations in ABL kinase domain are associated with inferior progression-free survival
- (2010) Pratibha Sharma et al. LEUKEMIA & LYMPHOMA
- Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
- (2009) M. C. Muller et al. BLOOD
- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- (2009) S. Soverini et al. BLOOD
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression
- (2008) Jamshid S. Khorashad et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started